EXAS stock | 51% gain in 1W

 What's Happening With EXAS?

Published on: 11/25/2025

 

Exact Sciences (EXAS) stock hit day 6 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 51% return. The company has gained about $6.4 Bil in value over the last 6 days, with its current market capitalization at about $19 Bil. The stock remains 79.8% above its value at the end of 2024. This compares with year-to-date returns of 14% for the S&P 500.

 

Exact Sciences witnessed a robust streak, largely ignited by news of Abbott's $21 billion acquisition at $105/share. This strategic move, coupled with recent record Q3 revenue and the successful launch of its Cancerguard test, propelled the cancer diagnostics leader higher as investors priced in the substantial premium.

 

What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. Our take: There is a near-equal mix of good and bad in EXAS stock given its overall Moderate operating performance and financial condition. But keeping in mind its Very High valuation, we think that the stock is Unattractive (see Buy or Sell EXAS).

 

For quick background, EXAS provides cancer screening and diagnostic tests, including a non-invasive stool-based DNA test for colorectal cancer and gene expression tests for breast, prostate, and colon cancers.